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Abstract
Background: Migraine is one of the most common neurological diseases and an estimated 1.04 billion people
worldwide have been diagnosed with migraine. Available data suggest that migraine is world widely associated
with a high economic burden, but there is great variability in estimated costs that depends on the geographical,
methodological and temporal differences between the studies. The purpose of this study was to quantify the
annual direct cost of episodic migraine (EM) and chronic migraine (CM), both for the patient and for the National
Health System (NHS), using data from subjects who attended an Italian tertiary headache centre. Furthermore, we
evaluated comparatively the impact of gender and age on the economic burden of migraine.
Methods: We conducted a retrospective and non-interventional observational analysis of the electronic medical
records of subjects with EM and CM who consecutively attended the Regional Referral Headache Centre of Rome
and undergoing continuous treatment in the 2 years prior to 31 January 2019. This approach was intended to
prevent distorsions due to natural fluctuations in migraine status over time. The collected data included demographic
characteristics, number of specialist visits, consumption of medications, diagnostic tests, accesses in the emergency
department (ED) and days of hospitalization due to the pathology.
Results: Our sample consisted of 548 patients (85.4% women and 14.6% men): 65.5% had CM and 34.5% had EM.
The average annual expenditure per patient was €1482. 82.8% of the total cost (€1227) was covered by the NHS.
The main item of expenditure were medications that represented 86.8% (€1286), followed by specialist visits
(10.2%), hospitalizations for (1.9%), diagnostic tests for (1%) and ED visits for (0.1%). Costs were significantly higher
for women than men (€1517 vs. €1274, p = 0.013) and increased with age (p = 0.002). The annual direct cost of
CM was 4.8-fold higher than that of EM (€2037 vs. €427, p = 0.001).
Conclusion: Our results provide a valuable estimate of the annual direct cost of CM and EM patients in the specific setting
of a tertiary headache centre and confirm the high economic impact of migraine on both the NHS and patients.
Keywords: Cost of illness, Migraine, Chronic migraine, Episodic migraine, Burden of disease, Resource utilization, Cross
sectional
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
* Correspondence: andrea.negro@uniroma1.it
1Department of Clinical and Molecular Medicine, Sapienza University, Rome,
Italy
2Regional Referral Headache Centre, Sant’Andrea Hospital, Rome, Italy
Full list of author information is available at the end of the article
The Journal of Headache
                           and Pain
Negro et al. The Journal of Headache and Pain          (2019) 20:120 
https://doi.org/10.1186/s10194-019-1068-y
Introduction
Migraine is one of the most common neurological dis-
eases and it is estimated that around 1.04 billion people
worldwide have been diagnosed with migraine [1]. The
disease is described as moderate-to-severe headache at-
tacks that can last up to 72 h. The clinical course, at
least for patients who attend a headache centre, is char-
acterized by fluctuations from an episodic to a chronic
frequency of headache attacks [2]. The third edition of
the International Classification of Headache Disorders
(ICHD-3) sets the threshold for differentiating episodic
migraine (EM) from chronic migraine (CM) at 15 days
per month in the last 3 months [3]. Patients with CM
often overuse symptomatic drug that may lead to medi-
cation overuse headache (MOH) [4]. Almost daily mi-
graine attacks that do not respond to conventional
therapies define a refractory CM status [5]. Migraine, in
particular CM, is often associated with several comor-
bidities (e.g. vascular, cardiac, neurological, psychiatric,
and pain syndromes), which can complicate therapeutic
management [6].
In terms of disability, the Global Burden of Diseases
(GBD) has classified migraine as the second world cause
of years of life lived with disability (YLDs) [7], and the first
cause of YLDs in under 50s in both genders [8]. The full
burden and the impact of migraine emerge from the re-
cent results of “My Migraine Voice”, a survey conducted
on 11,266 adults with migraine for whom preventive treat-
ments have failed [9]. More than 85% of participants re-
ported that migraine limits their daily activities and
negatively affects their professional, private, and social life.
Migraine also has an important economic burden on
patients and society. “Cost of illness” is a methodology
that allows the economic evaluation of the cost (direct
and indirect) caused by illnesses on the population [10].
Direct costs are attributed to medical care for diagnosis,
treatment and rehabilitation and include consultations
with general practitioner (GP), specialist visits, diagnos-
tic tests, emergency department (ED) visits, hospitaliza-
tions, and medications er to treat headaches. Indirect
costs include the impact on functional capacity, resulting
in reduced social activities, loss of earnings, reduced
productivity, loss of education, job losses, unwanted job
changes and market replacement for lost domestic ser-
vices. There is a general agreement that a high percent-
age of patients never consult a physician for their
migraine and will never receive a diagnosis, while only a
small percentage regularly consults their physician [11,
12]. As a result, it is yet not possible to precisely quantify
the direct costs of migraine [10].
The available data suggest that CM is widely associated
with a higher economic burden than EM, but there is a
large variability in estimated costs that depends on the
geographical, methodological and temporal differences
between the studies [13–15]. Differences between coun-
tries in the annual cost of care are difficult to interpret be-
cause they could also be related to structural differences
in healthcare systems, available migraine therapies or dif-
ferences in awareness and migraine management.
The purpose of this study was to quantify and com-
pare the annual direct cost of EM and CM, both for the
patient and for the National Health System (NHS), using
the data of subjects attending an Italian tertiary level
headache centre. Furthermore, we comparatively evalu-
ated the impact of gender and age on the economic bur-
den of migraine.
Methods
The study is a cross-sectional cost-of-illness evaluation
of the direct cost, carried out on patients with EM and
CM who attended the Regional Referral Headache
Centre, Department of Clinical and Molecular Medicine,
Faculty of Medicine and Psychology, Sapienza University
of Rome.
Data source and participants
The data used for the current economic analysis come
from a retrospective and non-interventional observa-
tional analysis of the electronic medical records (EMR)
of all subjects with EM and CM (assessed with the
ICHD-3 [3]) who consecutively attended our tertiary
level headache centre and who were in continuous treat-
ment and underwent follow-up visits in the 2 years prior
to 31 January 2019 (data collection date). This approach
aimed to prevent distorsions due to the natural fluctua-
tions in episodic and chronic status over time [2]. Fur-
thermore, this method allowed a detailed assessment of
possible changes in dosage and in the class of pharmaco-
logical treatments that occurred during the visits.
Prophylactic drugs were prescribed at the daily dosages
suggested by the World Health Organization guidelines
[16], with the exception of onabotulinumtoxinA which
was used as quarterly injections of 195 U based on more
recent studies [17]. In our headache clinic, we ask our
patients to keep a headache diary to track the character-
istics of their headaches, drug use and use of healthcare
resource. The EMRs of the patients are updated at each
visit with the information obtained from the patient and
with the data extrapolated from the headache diary.
Participants were eligible for inclusion in the study if
they were ≥ 18 years old and if they had been in continu-
ous treatment for 2 years in order to guarantee the same
observation period for each enlisted subject.
Data on the use of health resources
The data collected included demographic characteristics,
number of specialist visits, number of diagnostic tests
(echocardiogram, carotid color doppler, brain / cervical
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magnetic resonance, brain computed tomography, radio-
graphs, blood tests), number of accesses in the emer-
gency department (ED), days of hospitalization due to
the pathology and consumption of medications (acute
and preventives).
Specialist visits and diagnostic tests are partially
funded by the NHS, while ED visits and hospitalizations
are entirely financed by the NHS. Depending on the
class of drug, symptomatic and prophylactic medications
may be or totally funded by the NHS or ma be partially
or totally charged to the patient. Acute non-specific mi-
graine medications and nutraceutics are responsibility of
the patient. Drug use was quantified by developing an al-
gorithm based on each prescribed drug and the daily
dosage (number of tablets or drops) multiplied by the
number of treatment days.
Economic study data
The direct cost estimates were the total of all that had
been paid or reimbursed by the NHS plus payments of
own pocket money Unit costs were collected from pub-
licly available sources in the calendar year 2019. The Re-
gional Rate Nomenclator for Specialist Outpatient was
considered for specialist outpatient services [18] while
each ED visit was considered to be €241 [19] and each
day of hospitalization with the diagnosis-related group
(DRG) 564 “Headache> 17 years” was considered equal
to €195 [20]. Medication costs were estimated using the
reimbursement price of the Regional Health System for
the classes of drugs charged to NHS [21], while the costs
of classes of drugs partially charged to the NHS or to-
tally charged to the patient were identified from a pri-
vate site for health care professionals.
Data analyses
Demographic and clinical characteristics, number of spe-
cialist visits, number of diagnostic tests, number of ED
visits, days of hospitalization, and consumption of drugs
(reimbursed and not reimbursed by the NHS) were eval-
uated descriptively. The total annual costs were derived
from the direct cost of 2 years of treatment and were
summarized based on the average and standard devi-
ation. The presence of statistically significant differences
between the groups was assessed by Chi-square test and
Fisher exact test, where appropriate, for the proportion,
Student’s T tests for normal distributions and Mann-
Whitney tests for non-normal distributions. The signifi-
cance level was set at 0.05 (always corrected if necessary)
for all variables.
Results
Participants characteristics
The analyzed sample consisted of 548 patients, 468
(85.4%) women and 80 (14.6%) men, aged between 18
and 84 years and an average of 52 years for both genders.
According to the ICHD-III diagnostic criteria, 359
(65.5%) subjects had CM and 189 (34.5%) had EM. CM
was more frequent than EM in both men (56.3% and
43.8%, respectively) and women (67.1% and 32.9%, re-
spectively), but not significantly.
Specialist visits
Subjects enrolled in the study received on average 6
follow-up visits during the 2 years of follow-up, corre-
sponding to a visit every 4months (Table 1). The average
number of specialist visits increased with age (p = 0.002)
and was higher for CM compared to EM (p < 0.0001)
while there was no difference by gender (Tables 1 and 2).
The average annual cost of specialist visits was €153, cov-
ered by the NHS for 39.2% (€60), and was higher for CM
than EM (€179 vs. €104, p < 0.0001) and increased with
age (p = 0.006) (Tables 3 and 4).
Diagnostic tests
The use of at least one diagnostic test during the 2 years
of follow-up involved 57 patients (10.4%), and the most
frequent examinations were brain MRI (59% of total ex-
aminations performed) and carotid color doppler (11%
of the total) (Table 1). The use of diagnostic tests was
higher among EM patients (p < 0.0001) (Table 2) while
there were no differences for gender and age (Table 1).
The diagnostic tests had an average cost per patient of
€15, covered by the NHS for 80% (€12). The cost was
significantly higher for EM than CM (€23 vs. €10, p <
0.0001) while there was no association with gender and
age (Tables 3 and 4).
ED visits and days of hospitalization
In the 2 years of observation, only 5 of 548 patients
(0.9%) entered the ED, while 26 patients (4.7%) had at
least one hospitalization (Table 1). The small sample of
patients who entered the ED did not allow any statistical
analysis. The number of days of hospitalization was
higher among CM patients (p = 0.002) and increased
with age (p = 0.044) while there were no significant dif-
ferences for gender (Table 2). The mean annual cost for
the NHS relating to the hospital management of patients
in terms of days of hospitalization was €28 per patient.
The cost was higher for CM than EM (€39 vs. €5, p =
0.003) without differences for gender and age (Tables 3
and 4).
Medications consumption
The use of acute and preventive mediactions and the use
of specific drugs classes varied according to gender, age
and migraine status (Table 5). Women used more cal-
cium channel blockers (p = 0.043) and nutraceutics (p =
0.028) while men used more ß-blockers (p = 0.003).
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Older age was associated with a reduction in the use
of triptans (p < 0.0001) and an increase in the use of sim-
ple analgesics (p = 0.011), antidepressants (p = 0.005), ß-
blockers (p = 0.016), onabotulinumtoxinA (p = 0.003)
and nutraceutics (p < 0.0001). As preventive medications,
patients with CM used more antidepressants (p = 0.000)
and anxiolytics (p < 0.0001) while EM patients used
more nutraceutics (p < 0.0001). Among acute medica-
tions, CM patients used more NSAIDs (p < 0.0001) and
simple analgesics (p = 0.020) while patients with EM
used more triptans (p = 0.035) and combination analge-
sics (p < 0.0001). The overall mean annual cost of medi-
cations was €1286 per patient, of which the 85.1%
accounted for preventive treatments. The mean annual
cost of acute medications was €191, covered by NHS for
the 87.9%, and was significantly higher for women and
CM patients and increased with age (Table 6). The mean
annual cost of prevenitve medications was €1095, cov-
ered by NHS for the 87.6%, and was significantly higher
for women (€1321 vs. €1079 for male, p = 0.010) and
CM patients (€1808 vs. €294 for EM, (p < 0.0001) and
increased with age (p < 0.0001) (Table 6).
Analysis of total costs
The average annual expenditure per patient was €1482
and the variability of expenditure per patient was high,
the spending range of was between €51 and €3644, with
an inter-quartile difference of €1666 (€511 - €2177) and
a coefficient of variation (standard deviation on the
arithmetic mean) of the 58.3%. 82.8% of the total cost
(€1227) was covered by the NHS. The main item of ex-
penditure was represented by medications that repre-
sented 86.8% (€1286), followed by specialist visits for
10.2% (€153), hospitalizations for 1.9% (€28), diagnostic
tests for 1% (€15) and ED visits for 0.1% (€1). Costs were
significantly higher for women than men (€ 1517 vs.
€1274, p = 0.013) and increased with age (p = 0.002)
(Table 7). The annual direct cost of CM was 4.8 times
higher than that of EM (€2037 vs. €427, p = 0.001) and
the difference in average total annual costs between CM
and EM was €1610 (Fig. 1).
Discussion
Last year, the drug paraphernalia for migraine prophy-
laxis was enriched with the 3 first-in-class monoclonal
antibodies (mAbs) acting on the calcitonin gene-related
peptide (CGRP) pathway [22]. The high cost of these
drugs requires an adequate selection of patient [23] and
probably it will be the same in a few years, when two
new classes of migraine-specific drugs (e.g., ditans and
gepants) will enter the market [24, 25]. Today more than
ever, health systems must face the difficult problem of
economic sustainability.
Our study provides a specific quantification of the an-
nual direct cost associated with CM and EM (assessed
with the ICHD-3 [3]) based on gender and age of pa-
tients in a large population of subjects attending an Ital-
ian tertiary level headache centre. The NHS funded
82.8% (€1227) of the annual cost of migraine (€1482)
while patients had an annual personal expenditure of
€255 as a contribution for specialist visits, diagnostic
tests, and medications. The annual cost of CM was
€2.037 and that of EM was €427. The cost charged to
the NHS was €1760 for CM and €212 for EM, while the
cost for the patient was €277 for CM and €215 for EM.
As expected in a headache center, the percentage of
patients with CM (65.5%) was significantly higher than
that estimated in the general population (2–4%) [26].
Table 2 Healthcare resource use in 2 years by migraine status
Diagnosis CM
(n = 359)
EM
(n = 189)
Total
(n = 548)
p-value
Specialist visits 6.8 3.9 5.8 < 0.0001
Diagnostic tests 24 33 57 < 0.0001
Hospitalizations 24 2 26 0.002
CM chronic migraine, ED emergency department, EM episodic migraine.
Table 3 Annual cost of specialist visits, diagnostic tests, hospitalizations and ED visits by gender, age and migraine status
Age MEN WOMEN
N. Specialist
visits
Diagnostic
tests
Hospitalizations DH visits Total N. Specialist
visits
Diagnostic
tests
ED visits Hospitalizations Total
NHS PRI NHS PRI NHS NHS NHS + PRI NHS PRI NHS NHS PRI NHS NHS + PRI
18-34 10 39 € 61 € 5 € 2 € 12 € 0 € 119 € 47 56 € 86 € 19 € 4 € 3 € 21 € 189 €
35-44 9 49 € 76 € 27 € 6 € 0 € 163 € 321 € 54 60 € 93 € 12 € 2 € 0 € 54 € 221 €
45-54 23 59 € 92 € 5 € 1 € 0 € 21 € 179 € 173 59 € 92 € 13 € 3 € 1 € 31 € 199 €
55-64 26 65 € 101 € 23 € 4 € 5 € 19 € 216 € 129 63 € 98 € 7 € 2 € 0 € 19 € 189 €
> 65 12 56 € 87 € 0 € 0 € 0 € 0 € 143 € 65 62 € 95 € 12 € 3 € 0 € 15 € 187 €
Total 80 57 € 88 € 13 € 3 € 3 € 30 € 194 € 468 61 € 94 € 12 € 3 € 1 € 27 € 196 €
CM chronic migraine, ED emergency department, EM episodic migraine, NHS National Health System, PRI private cost
Costs are calculated in 2019 Euros
The private contribution for specialist visits and diagnostic tests is calculated separately
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The costs for any item of expense were higher for
CM expecting the cost of diagnostic tests. The annual
cost of prophylaxis was €1095 of which 82% (€902/
year per patient) was due to onabotulinumtoxinA and
18% (€193/year per patient) due to oral preventives.
The entire sample of patients with CM was treated
with onabotulinumtoxinA and this explains how this
treatment had an impact on the annual cost esti-
mates. As a result, the number of visits to our head-
ache centre was almost double for CM compared to
EM due to the quarterly onabotulinumtoxinA injec-
tion program. Patients with CM, compared to those
with EM, have used significantly more antidepressants
and anxiolytics and this finding is consistent with the
greater impact that CM has on quality of life and
mood. CM is often associated with a loss of efficacy
of triptans and, indeed, the use of triptans was greater
among EM patients while CM patients used more
NSAIDs and simple analgesics. Furthermore, patients
with CM had 12 times more days of hospitalization
than patients with EM. As for the other expense
items, the highest cost observed in EM in terms of
diagnostic examination is surprising only since most
of the patients with CM had been in a chronic state
for several years and had already undergone a diag-
nostic investigation to exclude the biological cause
before attending our headache centre.
We decided to calculate the annual direct cost by ana-
lyzing the patients’ EMR in continuous treatment for 2
years to prevent distortions due to the natural fluctua-
tions in episodic and chronic status over time [2]. Drug
therapy can change considerably over the course of a
year to adapt to the clinical course of migraine. Follow-
ing this method it was possible to detect any changes in
dosage and class of drugs and, therefore, provide a better
estimates of the cost of pharmacological treatments.
This is a strength of our study compared to others who
have used annualization to adapt the survey data consid-
ering a time window of few months. Defining the annual
cost of migraine on the basis of a quarter multiplied by
four may be almost acceptable for medications use but
could overestimate diagnostic tests and hospital visits
that are likely to be compressed in the period near to
the first admission.
From November 2008 to August 2009, the Eurolight
study, a multinational cross-sectional survey, was con-
ducted in eight European countries (Lithuania, Germany,
The Netherlands, Luxembourg, Italy, Austria, France
and Spain) to estimate the annual direct (medications,
outpatient health care, hospitalizations and investiga-
tions) and indirect per-person costs (in 2009 Euros) for
migraine, tension type headache and MOH (assessed
with the ICHD-II [27]) on the base of 8412 self-
administered questionnaires [15]. The average total an-
nual cost of migraine per-person in all countries was
€1222 of which indirect costs accounted for 93%
(€1136). Amongst the direct costs of €86 the main con-
tributory categories were outpatient care (€30), followed
by diagnostic tests (€19), acute medications (€16),
hospitalization (€16) and preventive medications (€5).
However, the main uncertainty in the Eurolight esti-
mates is due to the large variation across countries.
Eurolight estimates were logically higher than previous
estimates for Austria (€885 vs. €768), Italy (€1034 vs.
€706), Lithuania (€297 vs. €152), Luxembourg (€1446 vs.
€965), and Netherlands (€1524 vs. €867) [28]. The esti-
mate for Italy was based on a sample size smaller than
ours (221 vs. 548 subjects, respectively).
In 2009 a systematic review used the preliminary
data provided by the Eurolight group, and therefore
different from those subsequently published for the
Eurolight study, and estimated in €222 (in 2009
Euros) the total annual (direct + indirect) cost per pa-
tient in Italy (in seven other European countries in
the range between €111 and €649) [29]. The estimates
presented in this report have been converted to real
Euro to remove the effect of price differences on the
comparison of resource use between countries. The
mean cost per subject with migraine in the eight
countries (€445) was lower than the estimates consid-
ered in 2004 (€590) [30] probably due to methodo-
logical differences between Eurolight and previous
studies [15]. However, the actual expenses in each in-
dividual country is better evaluated with nominal esti-
mates as those used in the Eurolight study, which can
be compared directly to other local expenses. Our es-
timate of annual direct cost per patient (€1482) was
significantly higher than that formulated by Eurolight
Table 4 Annual cost of specialist visits, diagnostic tests, hospitalizations and ED visits by gender, age and migraine status
Diagnosis N. Specialist visits Diagnostic tests ED visits Hospitalizations Total
NHS PRI NHS PRI NHS NHS NHS + PRI
CM 359 70 € 109 € 8 € 2 € 1 € 39 € 229 €
EM 189 41 € 63 € 19 € 4 € 1 € 5 € 132 €
Total 548 60 € 93 € 12 € 3 € 1 € 28 € 196 €
CM chronic migraine, ED emergency department, EM episodic migraine, NHS National Health System, PRI private cost
Costs are calculated in 2019 Euros
The private contribution for specialist visits and diagnostic tests is calculated separately
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(€86) [15]. This finding could have some possible ex-
planations. First, our estimates were based on the
amount of each individual medication consumed and
we used the market cost of each unit of these drugs
to calculate medical costs. In contrast, in the Euro-
light study the estimates were based on an average
Table 6 Annual cost of medications by gender, age and migraine status
Gender N. Acute
NHS
p-value Acute
PRI
p-value Preventive
NHS
p-value Preventive
PRI
p-value Acute
NHS + PRI
p-value Preventive
NHS + PRI
p-value
Men 80 131 € 0.007 23 € NS 819 € NS 106 € 0.009 154 € 0.010 925 € 0.013
Women 468 174 € 23 € 983 € 141 € 197 € 1124 €
Age N. Acute
NHS
p-value Acute
PRI
p-value Preventive
NHS
p-value Preventive
PRI
p-value Acute
NHS + PRI
p-value Preventive
NHS + PRI
p-value
18-34 57 139 € < 0.0001 17 € 0.045 625 € < 0.0001 126 € 0.039 156 € < 0.0001 751 € 0.003
35-44 63 206 € 39 € 902 € 154 € 245 € 1056 €
45-54 196 200 € 17 € 948 € 148 € 217 € 1096 €
55-64 155 163 € 22 € 1094 € 130 € 185 € 1223 €
> 65 77 84 € 33 € 1008 € 113 € 117 € 1120 €
Diagnosis N. Acute
NHS
p-value Acute
PRI
p-value Preventive
NHS
p-value Preventive
PRI
p-value Acute
NHS + PRI
p-value Preventive
NHS + PRI
p-value
CM 359 191 € 0.001 27 € NS 1451 € < 0.0001 139 € NS 218 € < 0.0001 1590 € < 0.0001
EM 189 123 € 16 € 24 € 132 € 139 € 155 €
Total 548 168 € 23 € 959 € 136 € 191 € 1095 €
CM chronic migraine, EM episodic migraine, NHS National Health System, PRI private cost.
Costs are calculated in 2019 Euros.
Table 7 Total annual direct cost per patient by gender, age and migraine status
Gender N. Specialist
visits
Diagnostic
tests
ED + Hospitalizations Acute
medications
Preventive
medications
PRI Total (±SD) p-
value
Men 80 57 € 13 € 33 € 131 € 819 € 220
€
1274 € (±
1772)
0.013
Women 468 61 € 12 € 28 € 174 € 983 € 260
€
1517 € (±
1685)
Age N. Specialist
visits
Diagnostic
tests
ED + Hospitalizations Acute
medications
Preventive
medications
PRI Total (±SD) p-
value
18-34 57 53 € 17 € 21 € 139 € 625 € 229
€
1085 € (±
1674)
0.002
35-44 63 59 € 14 € 70 € 206 € 902 € 287
€
1537 € (±
1772)
45-54 196 59 € 12 € 31 € 200 € 948 € 260
€
1510 € (±
1711)
55-64 155 64 € 10 € 20 € 163 € 1094 € 253
€
1602 € (±
1641)
>64 77 61 € 11 € 13 € 84 € 1008 € 242
€
1417 € (±
1649)
Diagnosis N. Specialist
visits
Diagnostic
tests
ED + Hospitalizations Acute
medications
Preventive
medications
PRI Total (±SD) p-
value
CM 359 70 € 8 € 40 € 191 € 1451 € 277
€
2037 € (± 924) 0.001
EM 189 41 € 19 € 6 € 123 € 24 € 215
€
427 € (± 436)
Total 548 60 € 12 € 29 € 168 € 959 € 255
€
1482 € (±
1705)
CM chronic migraine, DH day hospital, ED emergency department, EM episodic migraine, PRI private cost.
Costs are calculated in 2019 Euros.
The private contribution for specialist visits, diagnostic tests and medications is calculated separately.
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cost per drug. Furthermore, the cost of prophylactic
medication was estimated on the assumption that
usage reported was stable over time and costs of rec-
ommended daily doses were multiplied by 365 days to
estimate annual costs. Secondly, Eurolight was con-
ducted before the introduction of onabotulinumtox-
inA that entailed an average annual cost per patient
of €902 in our population. Thirdly, Eurolight did not
take into account the cost of alternative pharmaco-
logical treatments, such as nutraceutics, which had an
average annual cost of €82 per patient. Other import-
ant differencies between our study and Eurolight are
related to the populations studied. First, the Eurolight
participants were drawn, depending on the country of
enrollment, from the general population or among
those who visited GPs or neurologists for any reason.
On the contrary, our population was composed of pa-
tients who attended a tertiary level headache centre
and who, therefore, were presumably more severely
affected than those enrolled in Eurolight. Secondly,
the different setting (e.g. headache centre vs. general
population) can easily explain why our population
was composed mostly of patients with CM (65.5%).
Furthermore, Eurolight considered the cost of mi-
graine patients as a whole population without differ-
entiating the costs of EM and CM. Although all these
differences make it difficuly to compare the results,
we can assume that the direct cost in Eurolight was
probably underestimated.
In the same year of the Eurolight study, the Inter-
national Burden of Migraine Study (IBMS) [31] evalu-
ated the direct medical costs of CM and EM (assessed
with the ICHD-II [27]) in North America (U.S. and
Canada) [13] and Western Europe (Germany, France,
Italy, Spain, and UK) [14] using global cross-sectional
data collected through a web survey administered from
February to April 2009. IBMS investigated the use of
healthcare resource occurred in the previous 3months
and multiplying the 3-months average healthcare cost by
4. The direct medical cost were calculated in 2010 U.S.
or Canadian dollars for North America, and standard-
ized to 2010 euros for Europe and the UK. CM status
was associated with significantly higher use of medical
resources and total costs compared to EM in all study
countries [13, 14]. CM participants had more provider
visits, ED and hospital visits, and diagnostic tests. The
Fig. 1 Mean total annual costs per patient by migraine group
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mean direct cost of care varied widely in the five Euro-
pean countries suggesting differences in migraine man-
agement, organization of NHS and reimbursements. The
number of subjects evaluated in each country was in the
range 55–57 for the CM group and in the range 644–
1404 for the EM group. Overall, the annualized costs of
care for EM were highest in Spain followed by the UK,
Italy, Germany and France. The costs of CM medical
care were highest in the UK followed by Spain and Italy
and then France and Germany. The IBMS study showed
that in Europe the average direct cost of CM was about
three times higher than that of EM (€2427/year and
€746/year, respectively) [14]. In particular, costs were
3.6-fold higher in UK (€3718 vs. €866/year), 2.3-fold
higher in France (€1579 vs. €486/year), 1.5-fold higher in
Germany (€1495 vs. €696/year), 2.5-fold higher in Italy
(€2648 vs. €828/year), and 2-fold higher in Spain (€2669
vs. €1092/year). The difference between the average total
annual costs between CM and EM was €2852 in UK,
€1093 in France, €799 in Germany, €1820 in Italy and
€1577 in Spain. Considering the Italian estimates, the
annual cost for CM was €2648 and the cost of EM was
€828. Our results showed lower costs for both groups
(€2037 and €427, respectively; difference CM-EM:
€1610) but unlike the IBMS study, we did not evaluate
the cost of GPs or other specialist visits, nurse practi-
tioners/physicians, transcutaneous nerve stimulators, oc-
cipital nerve block procedures and acupuncture.
However, the estimates of IBMS were based on patients
with primary headaches that were drawn from a pool of
registered panelists who expressed willingness to
complete health surveys in general, without reference to
headache. This explain why 95.1% of the population was
made up of EM patients and only 4.9% of CM. On the
contrary, we found a proportion between EM an CM
(35.5% and 65%, respectively) which was different from
that found in the general population which reflects the
greater severity of the patients who turns to a tertiary
level headache centre.
Unlike the studies mentioned above, ours had the
main purpose of assessing the direct cost in the specific
setting of a tertiary level headache centre. Two other
studies, both conducted in Italy, evaluated the healthcare
costs of patients attending a headache centre. The popu-
lation investigated in both studies was smaller than ours.
D’Amico et al. [32] evaluated the direct and indirect
costs of CM and MOH (assessed with the ICHD-3-beta
[33]) at the time of structured withdrawal in a headache
centre. The estimates were based on the 3-months
evaluation. Based on data from 135 patients, the total
annual cost per person was estimated at around €10,370,
of which €3495 (34%) due to direct healthcare cost, €515
(5%) due to direct non-medical cost and €6360 (61%)
due to indirect cost. Our estimate of direct costs is lower
(€1482) and this could depend on the different popula-
tion studied (CM and EM vs. CM and MOH). However,
the authors have not distinguished the costs of individ-
ual items within each expense category and this makes it
difficult to compare their estimate with ours. The cost of
prophylaxis (oral preventives and onabotulinumtoxinA)
was estimated at €215/year per patient, but the cost of
individual drug classes was not provided. We estimated
that the annual cost of prophylaxis was €1095 of which
82% (€902/year per patient) is due to onabotulinumtox-
inA and 18% (€193/year per patient) is due to oral pre-
ventives. In the same study, the annual cost of non-
pharmacological treatments (nutraceuticals and behav-
ioral approaches) was €1867 per patient. The cost of in-
dividual items of expenditure is not provided but the
high cost was probably due to the contribution of behav-
ioral approaches rather than nutraceuticals, while for the
latter our study estimated an annual cost of €83 per pa-
tient. Also for the cost of diagnostic procedures (e.g.
physician visits, diagnostic tests, hospitalizations), esti-
mated at €1296/year per patient, the contribution of the
individual expense items was not provided. In our study
the combined cost of those three items of expenditure
was much lower (€101/year per patient) and this could
be explained by a greater number of hospitalizations
among patients with MOH.
Berra et al. conducted another Italian study that ad-
dressed annual direct healthcare costs (in 2013 Euros)
in a tertiary level headache centre [34]. The costs
were estimated using ad hoc questionnaire on medical
resource use during the previous 3 months. Based on
data from 92 patients (51 with CM and 41 with EM,
assessed with the ICHD-3-beta [33]), the mean annual
cost was €1480. The annual cost of CM (€2250) was
4.3-fold higher than that of EM (€523). The cost
loaded on NHS was €2110 for CM and €468 for EM,
while the cost for the patient was €140 for CM and
€55 for EM. In our study we considered the same
categories of expenses and found almost overlapping
results with an average cost of €1482 per year. Also,
our estimates of the annual cost of CM (€2037) and
EM (€427) were similar to those proposed by Berra
et al. For our sample of patients, the cost charged on
the NHS was €1760 for CM and €212 for EM, while
the cost to the patient was €277 for CM and €215
for EM. The differences between their estimates and
ours emerge when we observe the contribution of the
individual expense items to the total cost. In their
study, the main item of expenditure was hospitaliza-
tions that accounted for 53.9% (in ours: 1.9%),
followed by medications for 32% (in ours: 86.8%),
diagnostic tests for 7.3% (in ours: 1%) and consulta-
tions for 6.8% (in ours: 10.2%). These differences may
have two main reasons. First, the large variation in
Negro et al. The Journal of Headache and Pain          (2019) 20:120 Page 10 of 12
the contribution of hospitalizations may depend on a
different approach in the management of migraine
patients. Second, in our study, medications were the
first leading expense and their contribution to the
total cost was nearly 3-fold higher than that estimated
by Berra et al. More in detail, we found that preven-
tives accounted for 85.1% and acute treatments for
14.9% of the total medications cost while Berra et.
found an opposite result with acute treatments ac-
counting for 78.2% and preventives for 21.8%. On the
other side, their population was represented by almost
the same number of CM and EM patients. In con-
trast, 65.5% of our patients had CM and were all
treated with onabotulinumtoxinA, thus explaining the
higher preventives expense.
Limitations of the study
This study is subjected to a number of limitations and
involved has several assumptions. Our analysis covered a
large population of 548 patients who attended our ter-
tiary level headache centre continuously for 2 years. Des-
pite this, our estimates cannot be generalized to all
Italian headache centres because treatment programs
and organizational management vary greatly between
different Italian regions.
As regards cost analysis, we calculated only the direct
costs strictly related to migraine but not the cost of dis-
orders that are comorbid or secondary to migraine or to
its treatment, which have a strong economic impact on
migraine management; including these conditions, costs
would of course increase even further. Our approach has
been designed to capture only the costs starting from
the first visit to our centre and related to our migraine
management. For this reason, we did not evaluate the
costs of the referring GPs (covered by NHS) or of proce-
dures (e.g. transcutaneous nerve stimulators, occipital
nerve block procedures and acupuncture) that for differ-
ent reasons are not used in our centre. Similarly, we did
not evaluate the costs of nurse practitioners, physicians
and resident doctors, which are entirely covered by the
NHS. A further limitation of this study is that we did
not calculate indirect costs and the impact of migraine
on family life; it would have required a different set-up
of the model used for the analysis and it was beyond our
aim of specifically calculate the direct costs.
Other limitations include possible selection bias to-
wards more severe migraine participants. Patients at-
tending a third-level headache center often have a
history of treatment failures and treatment attempts by
general practitioners; indeed, our sample consisted of
65.5% of patients with CM, while the prevalence of CM
is much lower. The costs are higher in the CM because
patients with a high frequency of attacks require more
frequent visits and need more treatments. The selection
of more severe patients than those from questionnaire-
based surveys based on ICHD criteria can explain why
our cost estimates are higher than those found in some
previous studies. Therefore, our estimates may not re-
flect the costs in the general population.
Another important limitation is that the use of healthcare
resource has been calculated based on the basis of data from
patients’ EMRs and there may be the possibility that patients
omitted some information or that doctors have not regis-
tered them into the EMR, as there is the possibility that pa-
tients have not correctly reported all events in their diary.
Health records maintained by national health insurance
funds could have provided more reliable data, but they would
have created other types of bias considering that the Italian
NHS provides universal coverage. However, we believe that
the methodology used in our study is a step forward com-
pared to the annualization of data based on self-administered
questionnaires for the previous 3–4months.
Conclusions
Our results provide a valuable estimate of the annual direct
cost of patients with CM and EM in the specific setting of a
tertiary level headache centre and confirm the high economic
impact of migraine on both the NHS and patients. Patients
with CM have had more visits, diagnostic tests and drug use
than patients with EM, which led to a direct annual cost of
4.8 times that of EM. Furthermore, costs were significantly
higher for women than for men and increased with age.
Cost of illness studies become obsolete due to the
change the healthcare systems and the availability of
new treatments become available. Governments and de-
cision makers should strongly support these investiga-
tions to reveal the true economic and social impact of
migraine, particularly when it is chronic.
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